Medexus Pharmaceuticals (MDP) Stock Forecast & Price Target

C$2.82 +0.22 (+8.46%)

(As of 12/20/2024 05:17 PM ET)

Medexus Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 5 Analyst Ratings

Sell
0

Hold
0

Buy
5

Based on 5 Wall Street analysts who have issued ratings for Medexus Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 3 have given a buy rating, and 2 have given a strong buy rating for MDP.

Consensus Price Target

C$5.25
86.17% Upside

According to the 5 analysts' twelve-month price targets for Medexus Pharmaceuticals, the average price target is C$5.25. The highest price target for MDP is C$8.25, while the lowest price target for MDP is C$3.50. The average price target represents a forecasted upside of 86.17% from the current price of C$2.82.

Get the Latest News and Ratings for MDP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medexus Pharmaceuticals and its competitors.

MDP Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	C$5.25	C$5.25	C$3.75	C$3.83
Forecasted Upside	86.17% Upside	146.48% Upside	47.06% Upside	75.04% Upside
Consensus Rating	Buy	Buy	Strong Buy	Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

MDP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Medexus Pharmaceuticals Stock vs. The Competition

Type	Medexus Pharmaceuticals	Medical Companies
Consensus Rating Score	3.40	2.81
Consensus Rating	Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent MDP News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	Raymond James 4 of 5 stars	M. Freeman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	C$3.00 ➝ C$4.00	+86.05%
9/30/2024	Leede Financial 0 of 5 stars	D. Loe Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Speculative Buy	C$8.25	+208.99%
8/22/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy	C$3.00 ➝ C$3.50	+45.23%
8/12/2024	Stifel Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Keywood Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
6/26/2024	Ventum Cap Mkts Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Quenneville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2023	Bloom Burton Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Martin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
2/10/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		C$3.00 ➝ C$4.00	+198.51%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:07 AM ET.

MDP Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Medexus Pharmaceuticals is C$5.25, with a high forecast of C$8.25 and a low forecast of C$3.50.
: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 3 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDP shares.
: According to analysts, Medexus Pharmaceuticals's stock has a predicted upside of 86.17% based on their 12-month stock forecasts.
: Over the previous 90 days, Medexus Pharmaceuticals's stock had 1 upgrade by analysts.
: Medexus Pharmaceuticals has been rated by research analysts at Leede Financial, and Raymond James in the past 90 days.
: Analysts like Medexus Pharmaceuticals more than other "medical" companies. The consensus rating for Medexus Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MDP compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

>> Register for the Workshop Now

This page (TSE:MDP) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Stock Forecast & Price Target